STOCK TITAN

[8-K] Silexion Therapeutics Corp Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Form 3 snapshot: On 07/07/2025, Singapore-based investor Yip Tsz Yan purchased a majority interest in A SPAC II (Holdings) Corp. (“Sponsor”), giving her indirect voting and investment control over the Sponsor’s stake in A SPAC II Acquisition Corp. (ASUUF). The filing classifies Yip as a 10 % beneficial owner of the issuer.

  • Ordinary shares held (indirect): 5,000,000
  • Warrants held (indirect): to acquire 8,966,000 Class A ordinary shares
  • Exercise price: $11.50 per share
  • Warrant timing: Exercisable on the later of (i) completion of the SPAC’s initial business combination or (ii) 05/02/2023; expire five years after a business combination

The disclosure signals a change in the controlling ownership of the Sponsor, consolidating significant influence over the SPAC’s future merger decisions. If fully exercised, the warrants could add cash at $11.50 per share but would increase the share count by up to 8.97 million, creating potential dilution for existing holders.

Riepilogo del modulo 3: Il 07/07/2025, l'investitrice con sede a Singapore Yip Tsz Yan ha acquisito una quota di maggioranza in A SPAC II (Holdings) Corp. (“Sponsor”), ottenendo così il controllo indiretto del voto e degli investimenti sulla partecipazione dello Sponsor in A SPAC II Acquisition Corp. (ASUUF). La dichiarazione classifica Yip come proprietaria effettiva del 10% dell'emittente.

  • Azioni ordinarie detenute (indirettamente): 5.000.000
  • Warrant detenuti (indirettamente): per acquisire 8.966.000 azioni ordinarie di Classe A
  • Prezzo di esercizio: 11,50 $ per azione
  • Tempistica dei warrant: esercitabili al verificarsi dell'evento più tardivo tra (i) il completamento della prima fusione aziendale della SPAC o (ii) il 02/05/2023; scadono cinque anni dopo una fusione aziendale

La comunicazione indica un cambiamento nel controllo proprietario dello Sponsor, consolidando un’influenza significativa sulle future decisioni di fusione della SPAC. Se esercitati completamente, i warrant potrebbero portare liquidità a 11,50 $ per azione ma aumenterebbero il numero di azioni fino a 8,97 milioni, generando una possibile diluizione per gli azionisti attuali.

Resumen del formulario 3: El 07/07/2025, la inversora con sede en Singapur Yip Tsz Yan adquirió una participación mayoritaria en A SPAC II (Holdings) Corp. (“Patrocinador”), obteniendo así control indirecto sobre el voto y la inversión en la participación del Patrocinador en A SPAC II Acquisition Corp. (ASUUF). La presentación clasifica a Yip como propietaria beneficiaria del 10% del emisor.

  • Acciones ordinarias en posesión (indirectamente): 5.000.000
  • Warrants en posesión (indirectamente): para adquirir 8.966.000 acciones ordinarias Clase A
  • Precio de ejercicio: $11.50 por acción
  • Plazo de los warrants: Ejecutables al ocurrir lo que suceda más tarde entre (i) la finalización de la combinación inicial de negocios de la SPAC o (ii) el 02/05/2023; expiran cinco años después de una combinación de negocios

La divulgación indica un cambio en la propiedad controladora del Patrocinador, consolidando una influencia significativa sobre las futuras decisiones de fusión de la SPAC. Si se ejercen completamente, los warrants podrían aportar efectivo a $11.50 por acción pero aumentarían la cantidad de acciones hasta en 8,97 millones, lo que podría diluir a los accionistas existentes.

서식 3 요약: 2025년 7월 7일, 싱가포르에 본사를 둔 투자자 Yip Tsz Yan이 A SPAC II (Holdings) Corp. (“스폰서”)의 과반 지분을 매입하여 스폰서가 보유한 A SPAC II Acquisition Corp. (ASUUF) 지분에 대한 간접적인 의결권 및 투자 통제권을 확보했습니다. 해당 신고서에서는 Yip을 발행사의 10% 실질 소유주로 분류하고 있습니다.

  • 보유 보통주 (간접): 5,000,000주
  • 보유 워런트 (간접): 클래스 A 보통주 8,966,000주 취득 가능
  • 행사가격: 주당 $11.50
  • 워런트 행사 시기: SPAC의 초기 사업 결합 완료 또는 2023년 5월 2일 중 늦은 시점부터 행사 가능; 사업 결합 후 5년 만료

이 공시는 스폰서의 지배권 변경을 알리며, SPAC의 향후 합병 결정에 대한 중요한 영향력을 강화합니다. 워런트가 모두 행사될 경우 주당 $11.50의 현금이 유입되지만, 최대 897만 주까지 주식 수가 증가하여 기존 주주들에게 희석 효과가 발생할 수 있습니다.

Résumé du formulaire 3 : Le 07/07/2025, l'investisseuse basée à Singapour Yip Tsz Yan a acquis une participation majoritaire dans A SPAC II (Holdings) Corp. (« Sponsor »), lui conférant un contrôle indirect sur les droits de vote et d'investissement de la participation du Sponsor dans A SPAC II Acquisition Corp. (ASUUF). Le dépôt la classe comme propriétaire bénéficiaire à 10 % de l'émetteur.

  • Actions ordinaires détenues (indirectement) : 5 000 000
  • Bons de souscription détenus (indirectement) : pour acquérir 8 966 000 actions ordinaires de classe A
  • Prix d'exercice : 11,50 $ par action
  • Calendrier des bons : exerçables à la date la plus tardive entre (i) la réalisation de la première fusion d'entreprise de la SPAC ou (ii) le 02/05/2023 ; expirent cinq ans après une fusion d'entreprise

Cette divulgation signale un changement dans la propriété contrôlante du Sponsor, consolidant une influence significative sur les futures décisions de fusion de la SPAC. En cas d'exercice complet, les bons pourraient apporter des liquidités à 11,50 $ par action, mais augmenteraient le nombre d'actions jusqu'à 8,97 millions, créant une dilution potentielle pour les actionnaires existants.

Formular 3 Zusammenfassung: Am 07.07.2025 erwarb die in Singapur ansässige Investorin Yip Tsz Yan eine Mehrheitsbeteiligung an A SPAC II (Holdings) Corp. („Sponsor“) und erlangte damit indirekte Stimm- und Investitionskontrolle über den Anteil des Sponsors an A SPAC II Acquisition Corp. (ASUUF). Die Einreichung klassifiziert Yip als 10% wirtschaftliche Eigentümerin des Emittenten.

  • Indirekt gehaltene Stammaktien: 5.000.000
  • Indirekt gehaltene Warrants: zum Erwerb von 8.966.000 Stammaktien der Klasse A
  • Ausübungspreis: 11,50 $ pro Aktie
  • Warrant-Zeitpunkt: Ausübbar ab dem späteren Zeitpunkt von (i) Abschluss der ersten Unternehmenszusammenführung der SPAC oder (ii) 02.05.2023; Verfall fünf Jahre nach einer Unternehmenszusammenführung

Die Offenlegung signalisiert eine Änderung der Kontrollbeteiligung am Sponsor und konsolidiert erheblichen Einfluss auf zukünftige Fusionsentscheidungen der SPAC. Bei vollständiger Ausübung könnten die Warrants Bargeld in Höhe von 11,50 $ pro Aktie zuführen, würden jedoch die Aktienanzahl um bis zu 8,97 Millionen erhöhen, was eine potenzielle Verwässerung für bestehende Aktionäre bedeutet.

Positive
  • Consolidated insider ownership may align Sponsor and investor interests by placing 5 M shares and 8.97 M warrants under single control.
  • Potential future capital infusion if warrants are exercised at $11.50, adding cash to the post-combination entity.
Negative
  • Potential dilution of up to 8.97 million shares if warrants are exercised.
  • Concentration of voting power in a single individual may raise governance and minority-shareholder concerns.

Insights

TL;DR: New individual gains control of Sponsor, holding 5 M shares and 8.97 M warrants; governance influence rises, dilution risk noted.

This Form 3 is primarily a governance event. By taking control of the Sponsor on 07/07/2025, Yip Tsz Yan now controls more than 10 % of ASUUF’s voting power, giving her a decisive voice in selecting the target for the SPAC’s eventual business combination. The filing also discloses warrants covering almost 9 million shares at $11.50. While exercise would provide capital, it represents a sizeable potential dilution once a deal closes. No immediate cash changes hands, and the shares are held indirectly, so the impact on near-term financials is limited. However, investors should monitor subsequent 13D filings and any changes in board composition or strategy that may follow.

Riepilogo del modulo 3: Il 07/07/2025, l'investitrice con sede a Singapore Yip Tsz Yan ha acquisito una quota di maggioranza in A SPAC II (Holdings) Corp. (“Sponsor”), ottenendo così il controllo indiretto del voto e degli investimenti sulla partecipazione dello Sponsor in A SPAC II Acquisition Corp. (ASUUF). La dichiarazione classifica Yip come proprietaria effettiva del 10% dell'emittente.

  • Azioni ordinarie detenute (indirettamente): 5.000.000
  • Warrant detenuti (indirettamente): per acquisire 8.966.000 azioni ordinarie di Classe A
  • Prezzo di esercizio: 11,50 $ per azione
  • Tempistica dei warrant: esercitabili al verificarsi dell'evento più tardivo tra (i) il completamento della prima fusione aziendale della SPAC o (ii) il 02/05/2023; scadono cinque anni dopo una fusione aziendale

La comunicazione indica un cambiamento nel controllo proprietario dello Sponsor, consolidando un’influenza significativa sulle future decisioni di fusione della SPAC. Se esercitati completamente, i warrant potrebbero portare liquidità a 11,50 $ per azione ma aumenterebbero il numero di azioni fino a 8,97 milioni, generando una possibile diluizione per gli azionisti attuali.

Resumen del formulario 3: El 07/07/2025, la inversora con sede en Singapur Yip Tsz Yan adquirió una participación mayoritaria en A SPAC II (Holdings) Corp. (“Patrocinador”), obteniendo así control indirecto sobre el voto y la inversión en la participación del Patrocinador en A SPAC II Acquisition Corp. (ASUUF). La presentación clasifica a Yip como propietaria beneficiaria del 10% del emisor.

  • Acciones ordinarias en posesión (indirectamente): 5.000.000
  • Warrants en posesión (indirectamente): para adquirir 8.966.000 acciones ordinarias Clase A
  • Precio de ejercicio: $11.50 por acción
  • Plazo de los warrants: Ejecutables al ocurrir lo que suceda más tarde entre (i) la finalización de la combinación inicial de negocios de la SPAC o (ii) el 02/05/2023; expiran cinco años después de una combinación de negocios

La divulgación indica un cambio en la propiedad controladora del Patrocinador, consolidando una influencia significativa sobre las futuras decisiones de fusión de la SPAC. Si se ejercen completamente, los warrants podrían aportar efectivo a $11.50 por acción pero aumentarían la cantidad de acciones hasta en 8,97 millones, lo que podría diluir a los accionistas existentes.

서식 3 요약: 2025년 7월 7일, 싱가포르에 본사를 둔 투자자 Yip Tsz Yan이 A SPAC II (Holdings) Corp. (“스폰서”)의 과반 지분을 매입하여 스폰서가 보유한 A SPAC II Acquisition Corp. (ASUUF) 지분에 대한 간접적인 의결권 및 투자 통제권을 확보했습니다. 해당 신고서에서는 Yip을 발행사의 10% 실질 소유주로 분류하고 있습니다.

  • 보유 보통주 (간접): 5,000,000주
  • 보유 워런트 (간접): 클래스 A 보통주 8,966,000주 취득 가능
  • 행사가격: 주당 $11.50
  • 워런트 행사 시기: SPAC의 초기 사업 결합 완료 또는 2023년 5월 2일 중 늦은 시점부터 행사 가능; 사업 결합 후 5년 만료

이 공시는 스폰서의 지배권 변경을 알리며, SPAC의 향후 합병 결정에 대한 중요한 영향력을 강화합니다. 워런트가 모두 행사될 경우 주당 $11.50의 현금이 유입되지만, 최대 897만 주까지 주식 수가 증가하여 기존 주주들에게 희석 효과가 발생할 수 있습니다.

Résumé du formulaire 3 : Le 07/07/2025, l'investisseuse basée à Singapour Yip Tsz Yan a acquis une participation majoritaire dans A SPAC II (Holdings) Corp. (« Sponsor »), lui conférant un contrôle indirect sur les droits de vote et d'investissement de la participation du Sponsor dans A SPAC II Acquisition Corp. (ASUUF). Le dépôt la classe comme propriétaire bénéficiaire à 10 % de l'émetteur.

  • Actions ordinaires détenues (indirectement) : 5 000 000
  • Bons de souscription détenus (indirectement) : pour acquérir 8 966 000 actions ordinaires de classe A
  • Prix d'exercice : 11,50 $ par action
  • Calendrier des bons : exerçables à la date la plus tardive entre (i) la réalisation de la première fusion d'entreprise de la SPAC ou (ii) le 02/05/2023 ; expirent cinq ans après une fusion d'entreprise

Cette divulgation signale un changement dans la propriété contrôlante du Sponsor, consolidant une influence significative sur les futures décisions de fusion de la SPAC. En cas d'exercice complet, les bons pourraient apporter des liquidités à 11,50 $ par action, mais augmenteraient le nombre d'actions jusqu'à 8,97 millions, créant une dilution potentielle pour les actionnaires existants.

Formular 3 Zusammenfassung: Am 07.07.2025 erwarb die in Singapur ansässige Investorin Yip Tsz Yan eine Mehrheitsbeteiligung an A SPAC II (Holdings) Corp. („Sponsor“) und erlangte damit indirekte Stimm- und Investitionskontrolle über den Anteil des Sponsors an A SPAC II Acquisition Corp. (ASUUF). Die Einreichung klassifiziert Yip als 10% wirtschaftliche Eigentümerin des Emittenten.

  • Indirekt gehaltene Stammaktien: 5.000.000
  • Indirekt gehaltene Warrants: zum Erwerb von 8.966.000 Stammaktien der Klasse A
  • Ausübungspreis: 11,50 $ pro Aktie
  • Warrant-Zeitpunkt: Ausübbar ab dem späteren Zeitpunkt von (i) Abschluss der ersten Unternehmenszusammenführung der SPAC oder (ii) 02.05.2023; Verfall fünf Jahre nach einer Unternehmenszusammenführung

Die Offenlegung signalisiert eine Änderung der Kontrollbeteiligung am Sponsor und konsolidiert erheblichen Einfluss auf zukünftige Fusionsentscheidungen der SPAC. Bei vollständiger Ausübung könnten die Warrants Bargeld in Höhe von 11,50 $ pro Aktie zuführen, würden jedoch die Aktienanzahl um bis zu 8,97 Millionen erhöhen, was eine potenzielle Verwässerung für bestehende Aktionäre bedeutet.



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 14, 2025

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands
 
001-42253
 
N/A
(State or other jurisdiction
 
(Commission File Number)
 
(I.R.S. Employer
of incorporation)
 

 
Identification No.)

 

12 Abba Hillel Road

Ramat-Gan, Israel

 
5250606
(Address of principal executive offices)
 
(Zip Code)

+972-3-7564999
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 5.07. Submission of Matters to a Vote of Security Holders.
 
On July 14, 2025, Silexion Therapeutics Corp (the “Company”) reconvened its 2025 annual general meeting (the “Meeting”), after the Meeting had been adjourned on its originally scheduled date of July 7, 2025 due to the absence of a quorum. At the reconvened Meeting, holders of a total of 1,054,899 ordinary shares, constituting approximately 12.1% of the Company’s outstanding ordinary shares, were present in person or by proxy. In accordance with Article 21.3 of the Company’s amended and restated articles of association (the “Articles”), after a half-hour elapsed from the start time of the reconvened Meeting and a quorum (constituted by holders of a majority of the Company’s issued and outstanding ordinary shares) was not present, those shareholders present constituted a quorum for the conduct of business at the Meeting.

At the reconvened Meeting, the Company’s shareholders approved the following numbered proposals (and, in the case of Proposal 1, each sub-proposal), each of which was presented for a vote at the Meeting and approved by an ordinary majority of the Company’s shareholders, constituting the requisite majority required for approval under the Articles:

Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Ordinary Shares, par value $0.0009 per share
 
SLXN
 
The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $103.50 per share
 
SLXNW
 
The Nasdaq Stock Market LLC

(1) Election of each of Ilan Hadar, Dror J. Abramov, Ruth Alon, Ilan Levin, Avner Lushi, Shlomo Noy and Amnon Peled as a director serving on the Company’s board of directors (the “Board of Directors”) until the next annual general meeting of the Company and until his or her successor is elected and qualified:

Name of Director Nominee
 
Number of Votes and % of Votes in Favor (Excluding Abstentions)
 
Number of Votes and % of Votes Against (Excluding Abstentions)
 
Abstentions
 
Ilan Hadar
 
744,636
(96.9%)
 
23,478
(3.1%)
 
286,785
 
Dror J. Abramov
 
744,461
(96.9%)
 
23,653
(3.1%)
 
 
286,785
 
Ruth Alon
 
523,900
(68.2%)
 
244,189
(31.8%)
 
 
286,810
 
Ilan Levin
 
523,080
(68.1%)
 
245,034
(31.9%)
 
 
286,785
 
Avner Lushi
 
743,411
(96.8%)
 
24,703
(3.2%)
 
 
286,785
 
Shlomo Noy
 
744,726
(97%)
 
23,263
(3%)
 
 
286,910
 
Amnon Peled
 
743,753
(97%)
 
23,361
(3%)
 
 
287,785




(2) Ratification of the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as independent public accountants to audit the accounts of the Company for the year ending December 31, 2025 and the additional period until the next annual general meeting of shareholders of the Company, and authorization of the Board of Directors to fix their remuneration in accordance with the volume and nature of their services, or to delegate to the audit committee thereof to do so:

Number of Votes and % of Votes in Favor (Excluding Abstentions)
 
Number of Votes and % of Votes Against (Excluding Abstentions)
 
Abstentions
1,031,698 (98.3%)
 
18,337 (1.7%)
 
4,864


(3) A proposal to allow the Board of Directors to effect a reverse share split of the Company’s ordinary shares at a ratio of 1-for-15 , whereby all issued and outstanding, and all authorized but unissued, ordinary shares, par value $0.0009, of the Company, will be consolidated on a 1-for-15 basis, into a lesser number of ordinary shares, par value $0.0135 per share, of the Company:
 
Number of Votes and % of Votes in Favor (Excluding Abstentions)
 
Number of Votes and % of Votes Against (Excluding Abstentions)
 
Abstentions
627,106 (59.6%)
 
425,200 (40.4%)
 
2,593


(4) An increase to the number of ordinary shares reserved for issuance under the Company’s 2024 Equity Incentive Plan by 1,271,859 ordinary shares, to 1,428,268 ordinary shares (which numbers of shares will be adjusted downwards proportionately based on the 1-for-15 ratio of the reverse share split under Proposal 3):

Number of Votes and % of Votes in Favor (Excluding Abstentions)
 
Number of Votes and % of Votes Against (Excluding Abstentions)
 
Abstentions
540,644 (58.3%)
 
386,904 (41.7%)
 
127,351



SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
SILEXION THERAPEUTICS CORP
 
 
Date: July 14, 2025
/s/ Ilan Hadar
 
Name:
Ilan Hadar
 
Title:
Chief Executive Officer
 

FAQ

Who became a 10% owner of ASUUF according to the Form 3?

The filing names Yip Tsz Yan as the new 10 % beneficial owner through control of the SPAC’s Sponsor.

How many ordinary shares does Yip Tsz Yan control?

She indirectly controls 5,000,000 ordinary shares of A SPAC II Acquisition Corp.

What warrants are disclosed in the Form 3 filing?

The Sponsor holds warrants to acquire 8,966,000 Class A ordinary shares at an exercise price of $11.50.

When do the warrants become exercisable and when do they expire?

They become exercisable after the SPAC’s business combination or 05/02/2023, whichever is later, and expire five years after a business combination.

What was the effective date of the ownership change?

The date of the event requiring the statement was 07/07/2025.

How is the ownership held—directly or indirectly?

All securities are held indirectly through the Sponsor, A SPAC II (Holdings) Corp.
Silexion Therapeutics Corp

NASDAQ:SLXN

SLXN Rankings

SLXN Latest News

SLXN Latest SEC Filings

SLXN Stock Data

7.08M
8.05M
6.29%
7.03%
11.6%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
Israel
RAMAT GAN